Gilead Sciences

News

XinThera buy builds Gilead’s cancer, inflammation pipeline

Gilead Sciences has bulked up its early-stage R&D portfolio with an agreement to buy XinThera, adding drugs targeting PARP for oncology and MK2 for inflammatory diseas

News

Gilead emerges victorious from HIV PrEP patent trial

A US court has sided with Gilead Sciences in a dispute with the US government centred on the use of HIV medicines for pre-exposure prophylaxis.

News

After FDA rejection, Gilead nears full EU nod for hep D drug

Gilead Sciences is on the brink of getting full approval for the first drug for hepatitis D virus (HDV) in the EU, after getting a positive opinion from the EMA’s human me

News

Gilead and US Government square up in court over PrEP

Gilead Sciences will go to court this week to argue that it does not need to pay the US Government a share of the profits it has made on the use of its HIV drugs for pre-e

News

NICE backs use of Gilead/Kite CAR-T via Cancer Drugs Fund

A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro

News